Margin Breakdown
| Operating Margin | (33.18432) | |
| EBITDA Margin | (0.406421) | |
| Gross Margin | 0.27 | |
| Profit Margin | (0.437211) |
Are Mednax (NYSE:MD) shareholders starting to hold back?
 | By Raphi Shpitalnik | Macroaxis Story |
Mednax Enterprise Value is projected to increase significantly based on the last few years of reporting. The past year's Enterprise Value was at 4.34 Billion. The current year Free Cash Flow is expected to grow to about 355.4 M, whereas Revenue Per Employee is forecasted to decline to about 300.8 K. The underlying objective of this short story is to digest Mednax as an investment oportunity for August. We will discuss why recent Mednax price moves suggest a bounce in August.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Ellen Johnson
Mednax is OVERVALUED at 18.38 per share with modest projections ahead. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mednax has an asset utilization ratio of 77.19 percent. This indicates that the company is making $0.77 for each dollar of assets. An increasing asset utilization means that Mednax Inc is more efficient with each dollar of assets it utilizes for everyday operations.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Mednax. Your research has to be compared to or analyzed against Mednax's peers to derive any actionable benefits. When done correctly, Mednax's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Mednax Inc.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Mednax Inc. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Mednax
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Mednax's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Mednax's Liquidity
Mednax financial leverage refers to using borrowed capital as a funding source to finance Mednax Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Mednax financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Mednax's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Mednax's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Mednax's total debt and its cash.
Mednax Gross Profit
Mednax Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Mednax previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Mednax Gross Profit growth over the last 10 years. Please check Mednax's gross profit and other fundamental indicators for more details.
Is Mednax valued correctly by the market?
The latest price surge of Mednax Inc may encourage shareholders to take a closer look at the firm as it closed today at a share price of 19.58 on 644,813 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in August. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.84. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Mednax Inc partners.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Mednax Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.